Table 1.
Baseline characteristics of the 1,936 cardiac surgery patients included in the study
| Statin Treatment | ||||
|
All patients n = 1936 |
Yes n = 1322 |
No n = 614 |
p value | |
| Clinical data | ||||
| Age [years] | 66+10 | 65+10 | 67+10 | 0.01 |
| Male, % | 99% | 99% | 99% | 0.46 |
| BMI [kg/m2] | 29.4+5.4 | 30+5.4 | 29+5.3 | 0.03 |
| Diabetes mellitus, % | 34% | 35% | 30% | 0.03 |
| Hypertension, % | 60% | 81% | 73% | 0.001 |
| Chronic lung disease, % | 23% | 22% | 26% | 0.06 |
| Peripheral vascular disease, % | 30% | 30% | 30% | 0.90 |
| Cerebrovascular disease, % | 22% | 22% | 21% | 0.49 |
| Current Smoking, % | 68% | 21% | 17% | 0.03 |
| History of myocardial infarction, % | 42% | 46% | 33% | <0.0001 |
| History of heart surgery, % | 9% | 9% | 9% | 0.82 |
| LV ejection fraction <50%, % | 41% | 42% | 47% | 0.05 |
| NYHA heart failure class III/IV, % | 35% | 33% | 39% | 0.01 |
| History of atrial fibrillation, % | 5.7% | 6.3% | 4.6% | 0.13 |
| Chronic kidney disease, % | 3.7% | 11% | 13% | 0.53 |
| Cardiomegaly, % | 27% | 25% | 31% | 0.01 |
| Preoperative medications | ||||
| BetaBlockers, % | 53% | 57% | 46% | <0.0001 |
| ACE-I or ARB, % | 72% | 73% | 69% | 0.59 |
| Gemfibrozil, % | 8% | 8% | 7% | 0.59 |
| Calcium Chanel blocker, % | 21% | 23% | 17% | 0.01 |
| Amiodarone, % | 16% | 16% | 17% | 0.31 |
| Diuretics, % | 41% | 40% | 43% | 0.13 |
| Digoxin, % | 8% | 7% | 12% | <0.0001 |
Continuous variables are expressed as mean + SD or median with interquartile range
Abbreviations: LV: left ventricular; NYHA:New York Heart Association; ACE-I: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker;BMI: Body Mass Index